NCT05008588Active, not recruitingPhase 1/2
Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct
Safety and Efficacy of Combined Conditioned Medium With Umbilical Cord Mesenchymal Stem Cells as A Novel Strategy for Acute Stroke Infarct
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
The purpose of this study was to determine the effectiveness of a combination of intranasal conditioned medium (CM) with intraparenchymal umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in acute stroke patients to induce neurogenesis.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 1 Aug 2021
- Start date
- May 2022
- Primary completion date
- Mar 2026
- Lead sponsor
- PT. Prodia Stem Cell Indonesia
- Diseases
- Stroke
- NCT number
- NCT05008588
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 15
- From May 2022 to the primary completion date, Mar 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are immunocompromised and/or who are receiving therapy immunosuppressive
Other illness
- Patients with recurrent stroke in the 6 months preceding the episode current stroke
- CT or MRI images show midline shift and bleeding transformation
- Patients who cannot have a CT or MRI examination due to their condition
- Patients with a history of malignant tumors or other severe neurologic conditions.
Lab values
- Patients with impaired renal and hepatic function after the onset of ischemic stroke: Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT) \> 5x the upper limit of normal values and a significant increase in urea-creatinine values
Other
- Participate in similar studies using CM and/or UC-MSC
Who the study is looking for
- Male or female aged 25-60 years diagnosed with ischemic stroke acute phase
- The patient has had a CT scan/MRI of the brain to assess ischemic territory
- The patient must have an NIH Stroke score of 8-20
- The patient or legal assistant has obtained detailed informed consent regarding the study protocol and agreeing to participate in the study
- Patients with The Glasgow Coma Scale (GCS) score \> 8
- Patients with Pt-APTT values within normal limits
Age in the registry: 25 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PT Prodia StemCell Indonesia Coordinator of this site? Confirm its status | Jakarta | Indonesia | Unknown status |
| Gatot Soebroto Hospital Coordinator of this site? Confirm its status | Jakarta Pusat | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.